Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC

NCT04718909 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

166

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma Non-resectable

Interventions

DRUG: Regorafenib + sintilimab
DRUG: Regorafenib

Sponsor

Second Affiliated Hospital of Guangzhou Medical University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]